SFB1399: Univ. Prof. Dr. med. Dr. rer. nat. Michal R. Schweiger

Academic education

1995 - 2002: Biochemistry Studies, Free University Berlin
1994 - 2001: Medical School, Free University and Charité University Hospital Berlin

Scientific degrees

01/2015: Board examination in Human Genetics, Charité University Hospital Berlin
01/2013: Habilitation in Experimental Medicine, Charité University Hospital Berlin
06/2008: M.D., Medical School, Charité University Hospital Berlin, (Grade: Summa cum laude highest honors) Supervisor: Prof. Dr. P.M. Howley, Department of Pathology, Harvard Medical School)
12/2005: PhD, Biochemistry, Free University Berlin, (Grade: Summa cum laude highest honors) Supervisor: Prof. Dr. P.M. Howley, Department of Pathology, Harvard Medical School)
10/2002: Dipl. Biochem., Biochemistry, Free University Berlin
11/2001: Graduation from Medical School, Charité University Hospital Berlin

Scientific career

2019 - present: W3 Lichtenberg professorship, Epigenetics and Tumor Genetics, University of Cologne
2015 - present: Attending physician Human Genetics, University Hospital of Cologne
2014 - present: W2 Lichtenberg professorship, Functional Epigenomics, University of Cologne
2007 - 2014: Junior research group leader ‘Cancer genomics’, Max Planck Institute for Molecular Genetics Berlin
2005 - 2007: Postdoctoral research fellow, Harvard Medical School, Boston (Group of Professor Peter Howley, M.D.)
2002 - 2005: PhD student, Harvard Medical School, Boston (Group of Professor Peter Howley, M.D.)

Honors/ Awards/ Memberships

2014 - present: W2 Lichtenberg Professorship of the Volkswagen Stiftung
2008: Robert Koch Charité Dissertation award
2003 - 2005: Fellowship from the ‚Studienstiftung des deutschen Volkes’
1995: 1st Place ‚Jugend Forscht‘ (region and land), special price environmental technology: ‚Hefe (Saccharomyces cerevisiae)-Ein biologischer Monitor für Schutz und Schaden.’

10 most relevant publications

Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, Schiermer U, Boerno S, Ramisch A, Leschber G, Timmermann B, Grohe C, Lüders H, Vingron M, Fichtner I, Klein S, Odenthal M, Büttner R, Lehrach H, Sültmann H, Herwig R, Schweiger MR. Epigenomic profiling of non-small lung cancer xenografts uncover LRP12 DNA methylation as predicitive biomarker for carboplatin resistance. Genome Med. 2018 Jul 10.
Hussong M, Kaehler C, Kerick M, Grimm C, Franz A, Timmermann B, Welzel F, Isensee J, Hucho T, Krobitsch S, Schweiger MR.The bromodomain protein BRD4 regulates splicing during heat shock.Nucleic Acids Res. 2017 Jan 9;45(1):382-394.
Lienhard M*, Grasse S*, Rolff J, Frese S, Schirmer U, Becker M, Börno S, Timmermann B, Chavez L, Sültmann H, Leschber G, Fichtner I, Schweiger MR*, Herwig R.* QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments. Nucleic Acids Res. 2016 Dec 1. * co-shared first/last authors
Hussong M, Börno ST, Kerick M, Wunderlich A, Franz A, Sültmann H, Timmermann B, Lehrach H, Hirsch-Kauffmann M, Schweiger MR. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis. 2014 Apr 24;5:e1195.
Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov.2012 Nov;2(11):1024-35.
Kerick M, Isau M, Timmermann B, Sültmann H, Herwig R, Krobitsch S, Schaefer G, Verdorfer I, Bartsch G, Klocker H, Lehrach H, Schweiger MR. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics. 2011 Sep 29;4:68
Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One. 2010 Dec 22;5(12):e15661.
Krawitz PM*, Schweiger MR*, Rödelsperger C, Marcelis C, Kölsch U, Meisel C, Stephani F, Kinoshita T, Murakami Y, Bauer S, Isau M, Fischer A, Dahl A, Kerick M, Hecht J, Köhler S, Jäger M, Grünhagen J, de Condor BJ, Doelken S, Brunner HG, Meinecke P, Passarge E, Thompson MD, Cole DE, Horn D, Roscioli T, Mundlos S, Robinson PN. Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome. Nat Genet. 2010 Oct;42(10):827-9. *co-shared first authors
Schweiger MR, Kerick M, Timmermann B, Albrecht MW, Borodina T, Parkhomchuk D, Zatloukal K, Lehrach H. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One. 2009 May;4(5):e5548.
Schweiger MR, You J, Howley PM. Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol. 2006 May;80(9):4276-85.

Patents

Prostate Cancer Markers. (US 20140051082 A1, US 14/112,370)
Microrna based method for diagnosis of colorectal tumors and of metastasis’ (WO 2014044827 A1)
Colorectal cancer markers’ (WO 2014026768 A1)

CV

Univ. Prof. Dr. med. Dr. rer. nat. Michal R. Schweiger